Results 131 to 140 of about 451,686 (317)

Environmental consequences of genetically modified plants

open access: yes, 1997
Environmental consequences of genetically modified ...
Guerche, Philippe, Pelletier, Georges
openaire   +2 more sources

Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

open access: yesMolecular Oncology, EarlyView.
Cyclin D1 overexpression altered the cell adhesion pathway, while cyclin D2 upregulation had less impact on pathway enrichment analysis. Multiple myeloma (MM) patients with cyclin D1 overexpression showed reduced CD56 expression and increased circulating tumor cells (CTC) levels, suggesting that cyclin D1 may contribute to MM cell dissemination ...
Ignacio J. Cardona‐Benavides   +13 more
wiley   +1 more source

Genetically modified plants: a systematic review [PDF]

open access: yesInternational Journal of Recent Scientific Research, 2017
Mukta Shrivastava, Masrat Jan
openaire   +2 more sources

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

open access: yesMolecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi   +12 more
wiley   +1 more source

Riqueza e composição de espécies de insetos visitantes florais de algodoeiro Bt e não-Bt

open access: yesArquivos do Instituto Biológico
O objetivo deste estudo foi verificar se existe diferença entre a comunidade de insetos visitantes florais do algodoeirogeneticamente modificado (Bt) e sua isolinha convencional (não-Bt).
C.C Dutra   +3 more
doaj  

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy